ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$59.32
−0.55%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +1.6%
- EBIT
- -8.9%
- EPS
- +18.0%
- Free cash flow
- +5.3%
- Operating cash flow
- +5.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -22.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -16.9%
- EBIT
- -14.4%
- Net income
- -16.5%
- EPS
- +3.2%
- Free cash flow
- +3.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026